Page 5 - Massive Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Massive Bio is launching personalized clinical research matching technology to reach 100 thousand cancer patients.

AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions Partnership - read this article along with other careers information, tips and advice on BioSpace

Massive Bio brings cancer genomics to the masses, to improve quality of care and minimize costs. Founded by Selin Kurnaz in 2014, Massive Bio is backed by investors that include 500 Startups, Arturo Loaiza-Bonilla, Aymen Elfiky, and UL Ventures and is headquartered in New York.

The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 6/2/2022 featuring funding details for Massive Bio, Kickoff, and much more.

AI Drug Development Investments Accelerated in 2020 News provided by Share this article Share this article MILTON KEYNES, England, Dec. 30, 2020 /PRNewswire/ -- The market for AI in Drug Development had a record year in 2020 with $2.9B new funding and a total funding in the industry reaching $9.2B. But while the annual investment value is reaching new heights, the number of funding rounds has continued its downfall. Emersion Insights has analysed the investment landscape and categorised the industry into Information Engines, Drug Design and Clinical Trials. AI in Drug Development - Completed...